Process Development To Improve Batch Yield Of XOFLX™ Lentiviral Producer Cell Lines

By Jade Kent, Robert Asatryan, Hannah Dunn, Matthew Peckett, Sherin Parokkaran Johny, Meenakshi Raghunath, Matthew Tridgett, Keith Meaney, Maria I Patrício, Qian Liu

Efficient lentiviral vector (LVV) production is critical for advancing cell and gene therapies. XOFLX™ producer cell lines eliminate the need for plasmid transfection, reducing costs and simplifying supply chains while improving process consistency. These cell lines have demonstrated up to nine-fold higher titres compared to traditional four-plasmid methods, making them a powerful alternative for LVV manufacturing. Process development strategies further enhance productivity: high-density cell culture significantly boosts early harvest titres, while multiple harvests across an extended production window maximize cumulative yield. The addition of a specialized supplement, Additive X, amplifies titres by two to four times, likely by reducing auto-transduction events.

Extended production without sodium butyrate offers a “slow and steady” approach for scenarios where enhancers cannot be used, maintaining cell viability for up to 11 days. Combined, these innovations support scalable, intensified LVV production and pave the way for continuous manufacturing workflows. Uncover how these strategies can transform efficiency and robustness in viral vector manufacturing.